Graham Parry
Stock Analyst at Citi
(2.16)
# 3,028
Out of 4,408 analysts
224
Total ratings
58.8%
Success rate
0.5%
Average return
Main Sectors:
Stocks Rated by Graham Parry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: AZN AstraZeneca PLC | Maintained: Buy | 18,000p | $13,200.00 | +36.36% | 8 | Jun 13, 2026 | |
| SWX: NOVN Novartis AG | Maintained: Buy | n/a | $120.22 | - | 50 | Jun 12, 2026 | |
| LON: GSK GSK plc | Maintained: Hold | n/a | $1,958.00 | - | 51 | May 29, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Hold | kr 275.00 → kr 290.00 | $287.70 | +0.80% | 5 | May 12, 2026 | |
| SWX: ROP Roche Holding AG | Maintained: Buy | n/a | $326.10 | - | 5 | Mar 10, 2026 | |
| EPA: SAN Sanofi | Maintained: Hold | €85.00 → €80.00 | $75.54 | +5.90% | 40 | Feb 20, 2026 | |
| SNY Sanofi | Maintained: Buy | n/a | $43.80 | n/a | 17 | Jan 31, 2025 | |
| GSK GSK plc | Maintained: Sell | $19 | $52.23 | n/a | 23 | Dec 6, 2024 | |
| NVS Novartis AG | Rated: Hold | $118 → $130 | $151.56 | n/a | 17 | Sep 11, 2024 | |
| BME: GRF Grifols, S.A. | Initiated Coverage: Buy | €20.00 | $9.09 | n/a | 1 | Sep 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 358p → 620p | $335.10 | n/a | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $88 | $124.30 | n/a | 1 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $50 | $26.00 | n/a | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $34 | $51.01 | n/a | 1 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $24.58 | n/a | 1 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $4.30 | n/a | 1 | Oct 26, 2017 |
AstraZeneca PLC
Jun 13, 2026
Maintained: Buy
Price Target: 18,000p
Current: $13,200.00
Upside: +36.36%
Novartis AG
Jun 12, 2026
Maintained: Buy
Price Target: n/a
Current: $120.22
Upside: -
GSK plc
May 29, 2026
Maintained: Hold
Price Target: n/a
Current: $1,958.00
Upside: -
Novo Nordisk A/S
May 12, 2026
Maintained: Hold
Price Target: kr 275.00 → kr 290.00
Current: $287.70
Upside: +0.80%
Roche Holding AG
Mar 10, 2026
Maintained: Buy
Price Target: n/a
Current: $326.10
Upside: -
Sanofi
Feb 20, 2026
Maintained: Hold
Price Target: €85.00 → €80.00
Current: $75.54
Upside: +5.90%
Sanofi
Jan 31, 2025
Maintained: Buy
Price Target: n/a
Current: $43.80
Upside: n/a
GSK plc
Dec 6, 2024
Maintained: Sell
Price Target: $19
Current: $52.23
Upside: n/a
Novartis AG
Sep 11, 2024
Rated: Hold
Price Target: $118 → $130
Current: $151.56
Upside: n/a
Grifols, S.A.
Sep 12, 2023
Initiated Coverage: Buy
Price Target: €20.00
Current: $9.09
Upside: n/a
Mar 7, 2023
Reiterated: Buy
Price Target: 358p → 620p
Current: $335.10
Upside: n/a
Mar 3, 2023
Maintained: Hold
Price Target: $88
Current: $124.30
Upside: n/a
Feb 28, 2023
Maintained: Hold
Price Target: $50
Current: $26.00
Upside: n/a
Sep 10, 2018
Downgraded: Hold
Price Target: $34
Current: $51.01
Upside: n/a
Sep 10, 2018
Downgraded: Sell
Price Target: n/a
Current: $24.58
Upside: n/a
Oct 26, 2017
Downgraded: Sell
Price Target: n/a
Current: $4.30
Upside: n/a